Biocytogen Pharmaceuticals Co., Ltd. has entered into a global licensing agreement with Merck KGaA, Darmstadt, Germany, for the use of Biocytogen’s RenMice platform.
 
Under the terms of the agreement, Merck KGaA, Darmstadt, Germany will have full access to Biocytogen’s RenMice platform to discover and develop fully human antibody therapeutics for an unlimited number of drug targets.
 
Merck KGaA, Darmstadt, Germany will be responsible for all clinical development, manufacturing, and commercialization, and will provide Biocytogen with development and regulatory milestone payments. The official agreement was reached after an initial evaluation period.
 
Dr. Yuelei Shen, founder, chairman and CEO of Biocytogen, said, “This agreement provides Merck KGaA, Darmstadt, Germany with one of the most advanced fully human antibody discovery platforms. We are pleased that Merck KGaA, Darmstadt, Germany recognized the potential of our RenMiceTM platform to accelerate antibody development for novel and challenging targets.”